Sanai Health Industry Group Co (FRA:WUP0) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:WUP0 Sanai Health Industry Group Co Ltd FRA:WUP0
37 GF Score
Price €0.02
GF Value €0.05
! 5 Warning Signs
View Full Analysis

What is Sanai Health Industry Group Co Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:WUP0
37GF Score
Sanai Health Industry Group Co Ltd FRA:WUP0
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sanai Health Industry Group Co (FRA:WUP0) Overvalued in 2026?

Based on GuruFocus' analysis, Sanai Health Industry Group Co stock appears to be undervalued. The current stock price of €0.02 is trading 58% below its estimated GF Value™ of €0.05.

Key valuation signals for FRA:WUP0:

  • Interest Received:
  • GF Value™: €0.05 vs. price of €0.02 (58% below fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the FRA:WUP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanai Health Industry Group Co Business Description

Other Exchanges 01889:Hong Kong
Address 57 Hung To Road, Unit 5, 7th Floor, Nanyang Plaza, Kwun Tong, Kowloon, Hong Kong, HKG
Sanai Health Industry Group Co Ltd is a Hong Kong-listed pharmaceutical company operating primarily in the People's Republic of China. Its core business is the development, manufacturing, marketing, and sale of pharmaceutical products, with a focus on traditional Chinese medicine and over-the-counter drugs, including its well-known "Sanai" branded remedies. The company also provides related software and consultancy services. In addition, it operates a finance leasing segment that offers financial leasing services. The pharmaceutical products segment generates the majority of group revenue, and the PRC remains its principal market. Customers include hospitals, pharmacies, distributors, and retail consumers across China. The company is headquartered in Hong Kong and derives its revenue mainly from product sales, supplemented by leasing income and service fees.
37GF Score

Get the complete analysis for FRA:WUP0

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.05
GF Value